跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
KEVZARA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
KEVZARA
Authorized
STANDARD
KEVZARA
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
69383b7038bc7c51
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
69383b7038bc7c51
Drug Approval Canada Name
KEVZARA
Product Name
KEVZARA
Status
Marketed
Status Date
2018-06-21
Original Market Date
2018-06-21
Din
02472988
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
90:24.20.92
Atc Original
L04AC14 SARILUMAB
Atc Name
l 04 ac 14
Aig Number
0158770002
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
SARILUMAB
200 MG / 1.14 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
69383b7038bc7c51
Type
Standard
Back to Health Canada Approvals